What's included KPV 10mg 5 vials Thymosin Alpha-1 10mg 5 vials BPC-157 10mg 5 vials Long-term structural repair inflammation Neuro-inflammation & Neuropathic Pain CellGenic pairs KPV, Thymosin Alpha-1, ARA-290, and BPC-157 for neuro-inflammation, neuropathic pain, and immune support
The ghrelin receptors, in return, have improved the patterns linked with growth hormone secretion from the hypothalamus of the pituitary gland in research subjects
CJC-1295 WITH DAC (Drug Affinity Complex): Standard protocol: Total weekly: 2mg Split into: 1mg twice weekly (Monday/Thursday) OR: Single 2mg injection weekly Duration: 12-16 weeks Conservative protocol: Total weekly: 1mg Single injection weekly Good for first-timers Still effective, lower cost Aggressive protocol: Total weekly: 3-4mg Split into 1.5-2mg twice weekly Used by advanced users Diminishing returns above 2mg for most Why DAC version: Long half-life (6-8 days) Sustained GH elevation Weekly or twice-weekly injections (convenient) Most popular version CJC-1295 WITHOUT DAC (Mod GRF 1-29): Standard protocol: Dose: 100mcg per injection Frequency: 2-3x daily Timing: With Ipamorelin doses Total weekly: 1.4-2.1mg (200-300mcg daily) Typical schedule: Morning: 100mcg CJC + 200mcg Ipamorelin Post-workout: 100mcg CJC + 200mcg Ipamorelin Before bed: 100mcg CJC + 200mcg Ipamorelin Why without DAC: Mimics natural GH pulses Doesn't desensitize pituitary More "natural" approach More frequent injections (downside) Which to choose: Choose WITH DAC if: Want convenience Don't want daily injections Okay with steady GH elevation Most people choose this Choose WITHOUT DAC if: Want natural pulsing GH Already injecting daily (stacking) Prefer physiological approach Don't mind multiple daily injections FREE TOOLS FAQ What does "stacking" peptides mean
Some notice increased appetite (a GH effect, usually mild)
IP3 might stimulate the controlled release of calcium ions (Ca) from intracellular storage compartments if formed
Its commercialization for therapeutic use in France is however prohibited (2014 EMA refusal) strict research use on European territory.
